“In the second half, we expect another 2 commercial launches in HIV and oncology while continuing to deliver clinical and commercial excellence across the portfolio.”

In context

“Daniel O'Day (Chairman and Chief Executive Officer): Thank you, Jacquie, and thanks, everyone, for joining us on today's call. As you'll see from today's results, Gilead has delivered another quarter of commercial excellence with base business sales up 10% year-over-year, our strongest second quarter growth in 3 years, driven by our HIV portfolio, Trodelvy and Livdelzi. This was also an exciting quarter of clinical execution with positive updates across our core therapeutic areas. Turning to HIV performance this quarter. Sales grew 12% year-over-year, driven by impressive Biktarvy and PrEP business growth. Yeztugo has quickly become the leading long-acting PrEP option for new patient starts. Quarterly PrEP sales doubled year-over-year, exceeding $1 billion for the first time. With a $4 billion annual run rate for our PrEP business and Biktarvy's continued strength, we are raising our full year HIV growth expectations to 9% to 10% year-over-year from prior guidance of 8% growth. We continue to advance our extensive HIV pipeline with potential new daily, weekly, monthly, twice yearly and yearly options. Later this month, we expect an FDA decision on our once-daily oral treatment combining bictegravir and lenacapavir. BIC/LEN has the potential to become the first dedicated switch regimen within our treatment portfolio, expanding the options we offer for virally suppressed people with HIV and further strengthening our leadership in the switch market. We shared detailed data from our positive Phase III ISLEND-1 and ISLEND-2 studies at the 2026 International AIDS Society Meeting. These data are expected to support the filing and potential launch of the first once-weekly oral HIV treatment regimen, islatravir plus lenacapavir in 2027. In oncology, Trodelvy sales were up 26% year-over-year, reflecting strong demand across both triple-negative and pretreated HR-positive HER2-negative metastatic breast cancer. We also secured additional approvals for Trodelvy this quarter in first-line metastatic triple-negative breast cancer across PD-L1 status. The acquisition of Tubulis has now closed, providing Gilead with an industry-leading ADC platform and promising clinical stage ADCs. At ASCO, we have shared encouraging Phase I efficacy and safety data for GS-8824, formerly known as TUB-040 in platinum-resistant ovarian cancer. In cell therapy, launch preparations are fully underway for anito-cel which is just 5 months to go until the PDUFA date. The completed acquisition of Arcellx has given us full ownership of anito-cel, enabling faster, more focused execution in multiple myeloma as well as the D-Domain binder platform for future opportunities in both autologous and in vivo CAR T. This was a strong quarter for our liver disease business with Livdelzi sales more than doubling year-over-year. Livdelzi continues to gain momentum as the leading second-line treatment for primary biliary cholangitis, or PBC. The recent positive Phase III IDEAL data further strengthened the opportunity for Livdelzi to reach more patients with PBC. We also launched Hepcludex in the U.S. this quarter as the first and only FDA-approved treatment for chronic hepatitis delta virus or HDV. In summary, it's been a very strong first half and second quarter with impressive revenue growth across therapeutic areas, 2 commercial launches and 3 positive Phase III readouts. In the second half, we expect another 2 commercial launches in HIV and oncology while continuing to deliver clinical and commercial excellence across the portfolio. With that, I'll hand it over to Johanna.”